New Obesity Protein Discovery may Lead to Better Therapy

By determining the structure of a key receptor in obesity, a new study has unlocked an opportunity for the development of new drugs, reports a new study. The findings of the study are published in the journal Science.// For the study, the scientists focused on a protein in the brain, the melanocortin four receptor (or MC4R). This receptor helps with regulating the body’s energy balance by controlling how much energy is stored as fat. Mutations in the gene that encodes the MC4R protein are linked to severe childhood obesity and other forms.

"A lot of people think obesity is a lifestyle choice," said Raymond Stevens, a USC Provost Professor and director of the Bridge Institute at the USC Michelson Center for Convergent Bioscience. "That’s just not true in all cases. Some people have mutations of this gene. And if they have mutations of this gene, many cannot control their eating. It’s this receptor causing this issue in the brain."

Severe obesity is often linked to other health issues. Recent data on coronavirus have shown that adults 65 and older who are severely obese are among the hardest hit by the illness, according to the Centers for Disease Control and Prevention.

Working with the iHuman Institute at ShanghaiTech University and the Life Sciences Institute at the University of Michigan, Stevens was interested in the MC4R as part of a larger effort to elucidate the structures of a class of proteins called G protein-coupled receptors that control many human functions. MC4R is among them.

As Stevens and his team began to tackle the MC4R structure, they looked for the world’s expert in this area and turned to Roger Cone at the University of Michigan Life Sciences Institute for help on the function of this important receptor.

Scientists at the University of Michigan discovered the MC4R and have been studying its biology and pharmacology for more than 25 years. Since then, four drugs have been developed to target melanocortin receptors in humans. The drug setmelanotide targets the MC4R to treat rare forms of syndromic obesity, which affects about 1 out of 1,500 people. However, the drug is not potent enough to treat dietary obesity -- a more common form of the disease.

Advertisement

By determining the structure of MC4R, the scientists were able to see how it binds to and interacts with other drug molecules. Knowing how the protein is configured will enable scientists to develop and test new therapies that can more precisely treat obesity.

Stevens and Cone, senior authors of the study, highlight the findings as an example of the importance and power of international collaboration. "We were able to contribute our knowledge of the MC4R to help further the structural biology studies," says Cone. "And key structural findings from the USC and iHuman Institute researchers are helping us answer more questions about how this receptor functions in human metabolism."

Advertisement

Source-Eurekalert